Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Direxion Daily Semiconductor Bull 3X Shares trades at $173.3. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ACAD | SOXL | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $300.77 |
52-Week Low | $20.06 | $23.99 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SOXL, a 3x leveraged semiconductor ETF, trades at $194.65, up 7.26% in 24 hours but remains in a bearish technical trend. Recent volatility includes a 16% single-day drop on July 1, 2026 (24/7 Wall Street), highlighting risks of leveraged decay. News sentiment is mixed, with JPMorgan advocating buying the chip dip while Morgan Stanley notes investor rotation away from semiconductors. Key support lies at $189, with resistance at $200.
Outlook is highly speculative due to leverage amplifying sector swings. Opportunities exist for tactical traders betting on semiconductor rebounds, but risks of rapid decay in choppy markets are severe. Long-term holders face structural erosion from volatility, making SOXL unsuitable for buy-and-hold strategies amid elevated sector uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
